FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

Fate Therapeutics (FATE) reported a loss of 33 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 47 cents. The company reported a loss of 54 cents per share in the year-ago period. The loss narrowed year over year due to higher collaboration revenues and lower R&D expenses. The company earned collaboration revenues of $6.8 million, which beat the Zacks Consensus Estimate of $1 million. The figure also increased from $0.9 million reported in the year-ago q ...